Results 51 to 60 of about 11,862,011 (403)

THE TREATMENT OF PSORIASIS WITH MYELOCENE. [PDF]

open access: yesThe Lancet, 1902
n ...
Watson, D. Chalmers   +1 more
openaire   +3 more sources

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients.

open access: yesActa Médica Portuguesa, 2018
INTRODUCTION Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction.
A. Azevedo   +3 more
semanticscholar   +1 more source

The Safety of Systemic Treatments That Can Be Used for Geriatric Psoriasis Patients: A Review

open access: yesDermatology Research and Practice, 2012
Background. Patients with moderate-to-severe psoriasis are often treated with systemic immunosuppressant agents that decrease immune system function. For the elderly, these medications are often problematic due to their already immunosuppressed state and
Jillian W. Wong, John Y. M. Koo
doaj   +1 more source

Effect of Narrow-Band Ultraviolet B Therapy of Psoriasis Vulgaris on Skin Directional Reflectance, Skin Density and Epidermal Thickness

open access: yesApplied Sciences, 2023
Psoriasis is an inflammatory dermatosis manifested by the appearance of brown-red papules on the body, covered with silver scales. One of the most common and effective treatments for psoriasis is narrow-band UVB phototherapy.
Wiktoria Odrzywołek   +5 more
doaj   +1 more source

Validating a Selective S1P1 Receptor Modulator Syl930 for Psoriasis Treatment.

open access: yesBiological and Pharmaceutical Bulletin, 2018
Psoriasis is a chronic inflammatory skin disease characterized by red, scaly and raised plaques. Thus far, T-cell infiltration is one of the most prominent pathogenic triggers, however, the exact molecular mechanisms underlying psoriasis have not been ...
M. Ji   +7 more
semanticscholar   +1 more source

Clinical consequences of antibody formation, serum concentrations, and HLA-Cw6 status in psoriasis patients on Ustekinumab [PDF]

open access: yes, 2019
Background: Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine.
Busard, Celine, I   +9 more
core   +1 more source

Real‐life self‐assessment of pruritus relief with a combination of calcipotriol/betamethasone dipropionate foam in patients with plaque psoriasis

open access: yesJEADV Clinical Practice, 2022
Objectives Psoriasis‐related pruritus is a frequent and underestimated symptom with a strong impact on quality of life, psychological condition and sleep.
Laurent Misery   +4 more
doaj   +1 more source

Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab [PDF]

open access: yes, 2020
Switching of biologic agents in treatment of plaque psoriasis is a common strategy. Only a few studies are available on switching between IL17A-blockers.
Amschler, K   +6 more
core   +1 more source

JAK3 as an emerging target for topical treatment of inflammatory skin diseases [PDF]

open access: yes, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Alves de Medeiros, Ana   +5 more
core   +2 more sources

The risk of developing psoriasis in alcohol-dependent patients and possible therapeutic strategies

open access: yesJournal of Education, Health and Sport, 2020
Excessive alcohol consumption significantly contributes to the damage of the nervous, cardiovascular and digestive systems. According to the latest scientific reports, excessive ethanol consumption might also contribute to an increased risk of developing
Iga Dudek   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy